Intra-tumoral heterogeneity, whereby distinct tumor cell populations with different molecular and phenotypic profiles form within the same tumor, is observed in cancers. This phenomenon poses a significant hurdle for cancer therapy as some evolving cell types are resistant to treatment.

Dr. Tuomas Tammela, who is based at the Memorial Sloan Kettering Cancer Center in New York, US, has been working to uncover the biological basis of tumor heterogeneity in lung adenocarcinoma (LUAD) and identify signaling pathways that dictate specific cellular phenotypes. He believes that understanding how and why tumors evolve from a single cell to a heterogenous tissue could direct the development of new therapeutic concepts aimed at reducing cellular heterogeneity in tumors. Read the whitepaper to find out more about his research.

All information presented is for informational purposes only and is not intended for medical advice.